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Gene therapy strategies  
for Alzheimer Disease 
AMYLOID-β PEPTIDE AGGREGATION 
 
     Its production originates from the amyloid precursor  
protein (APP) through γ-secretase processing (Fig. 2). 
Amyloid-β oligomers increase the neurons glutamate, leading 
to toxicity and posterior denervation (Fig. 1). 
 
 
 
 
 
 
 
 
 
 
   Fig. 1. Main pathways implicated in LTD facilitated by soluble Ab oligomers               Fig.2. APP cleavege processing signalling 
 
 
 
 
siRNA AND NEPRILYSIN GENE THERAPY 
The delivery of siRNA against APP mRNA forms a silencing complex that induces its cleavage. 
However, it might effect on the physiological role of APP. 
 
Neprilysin  on the other hand, is an endopeptidase that cleaves peptides of 4-5 kDa, including the 
amyloid-β peptide. 
 
Both experiments expressing neprilysin and siRNA  
against APP confirmed that recombinant gene  
therapy vectors successfully  decreased the levels 
 of amyloid-β peptide in vitro and in vivo conditions. 
 
 
 
 
 
 
   Fig. 4. schematic illustration of APP-RNAi construct                                   Fig. 5. Herpes simplex virus RNAi and neprilysin gene 
 
CHOLINERGIC NEURONS DEGENERATION 
 
 
 
 
The cholinergic neurons are nerve growth factor (NGF) dependent, establishing its  
survival and synapsis formation through axonal stimulation. 
 
There is a correlation between the aging and the reduction in the concentration of  
NGF and the efficiency of its signalling pathway. 
 
There is a loss of synapsis present in  
the ascendant cholinergic projections 
 from the nucleus basalis of Meynert  
to the hippocampus and neocortex. 
 
This is followed by the loss of NGF 
 producer neurons, and a decrease in 
 the neuronal activity. 
               Fig.3. NGF correlation with aging 
 
 
NGF GENE THERAPY 
After the treatment, the patients showed a median reduction in the decline of the score in 
both tests, MMSE and ADAS-Cog. 
 
Interestingly, some subjects not only stopped the degeneration in the early stages after 
treatment, but also showed an improvement. 
 
 
 
 
 
 
 
 
 
 
 
Fig.6. Mean annualized change in MMSE score                                   Fig.7. Mean annualized changes in ADAS-Cog 
 
 
 
INTRODUCTION 
Alzheimer Disease is the neurodegenerative disorder with the highest prevalence, mostly 
present in elders. The neuronal degeneration and loss of synapses progresses over time 
spreading through the brain. 
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There are TWO main pathways that cause Alzheimer disease: 
 
Degeneration of cholinergic neurons 
Accumulation of extracellular insoluble aggregates composed by amyloid-β peptide (Aβ)  
GENE THERAPY 
This technique consists in the delivery of nucleic acid polymers in the patient’s cell 
to either express a protein or interfere with a protein expression. 
 
Adeno-associated virus (AAV) are the best vector selection in Alzheimer disease 
due to its intrinsic safety characterization when utilized in the nervous system. 
 
 
CONCLUSION 
However, none of the gene therapy techniques successfully showed a fully recovery and functional restoration of the 
impaired brain areas, the cease in the deterioration of  cholinergic neurons as well as  β-amyloid plaques elimination could 
bring symptomatic mitigation and also stop the development of Alzheimer disease. 
 
Further studies are needed to clear the remaining uncertain molecular pathways involved in Alzheimer’s in order to 
enable the development of innovative gene based therapies.  
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